Cui, Xiao-Long
Nie, Ji
Zhu, Houxiang
Kowitwanich, Krissana
Beadell, Alana V.
West-Szymanski, Diana C.
Zhang, Zhou
Dougherty, Urszula
Kwesi, Akushika
Deng, Zifeng
Li, Yan
Meng, Danqing
Roggin, Kevin
Barry, Teresa
Owyang, Ryan
Fefferman, Ben
Zeng, Chang
Gao, Lu
Zhao, Carolyn W. T.
Malina, Yuri
Wei, Jiangbo
Weigert, Melanie
Kang, Wenjun
Goel, Ajay
Chiu, Brian C.-H.
Bissonnette, Marc
Zhang, Wei
Chen, Mengjie
He, Chuan
Funding for this research was provided by:
Foundation for the National Institutes of Health (R01 HG006827, R33 CA269100, R01 GM126553, R01 HG011883, U01 CA217078)
Article History
Received: 14 November 2023
Accepted: 29 April 2024
First Online: 14 June 2024
Declarations
:
: All experimental methods are in full compliance with the Helsinki Declaration. The informed consent form was obtained from each study participant before the study. All patients were consented under the protocol of IRB-10–209 A (PI: M.B.), which was approved by the University of Chicago Institutional Review Board.
: Not applicable.
: A patent application for the LABS has been filed by the University of Chicago. There is sufficient information in the manuscript to reproduce the work, and the patent does not prevent that. C.H. is a scientific founder, a member of the scientific advisory board and equity holder of Aferna Bio, Inc. and Ellis Bio Inc.; a scientific cofounder and equity holder of Accent Therapeutics, Inc.; and a member of the scientific advisory board of Element Biosciences and Rona Therapeutics. W.Z. is a consultant with Tempus Labs, Inc. for their biomarker discovery program. The other authors declare that they have no competing interests.